Literature DB >> 26763764

Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics.

Paul Glue1, Gavin Cape2, Donna Tunnicliff2, Michelle Lockhart3, Fred Lam4, Andrew Gray1, Noelyn Hung1, C Tak Hung4, Sarah Harland1, Jane Devane5, John Howes5, Holger Weis5, Lawrence Friedhoff6.   

Abstract

The aim of this study was to switch patients established on methadone opioid substitution therapy (OST) to morphine over 1 week. Subjects established on daily methadone OST (mean dose 60 mg/day) were switched to morphine slow-release capsules, dosed at 4× the previous total daily methadone dose, for 6 days, then given morphine syrup dosed q3h. All 27 subjects enrolled in this study completed the switch from methadone to morphine. Opioid withdrawal symptoms (OWS) peaked within 12-24 hours of starting morphine, and 24/27 subjects required higher daily morphine doses (mean 5.2× multiple). Pharmacokinetic evaluation showed that 91% of methadone was cleared during this time, with a mean elimination half-life of 59 hours. The most frequent treatment-emergent non-OWS adverse events were headache, nausea, constipation, and neck pain. The method described here appears to be a safe and acceptable approach to switch subjects from methadone to morphine.
© 2016, The American College of Clinical Pharmacology.

Entities:  

Keywords:  methadone; morphine; opioid substitution therapy; pharmacodynamics; pharmacokinetics; safety

Mesh:

Substances:

Year:  2016        PMID: 26763764     DOI: 10.1002/jcph.704

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  2 in total

Review 1.  Managing Pain in the Older Cancer Patient.

Authors:  Dylan Finnerty; Áine O'Gara; Donal J Buggy
Journal:  Curr Oncol Rep       Date:  2019-11-14       Impact factor: 5.075

2.  Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats.

Authors:  Lindsey R Hammerslag; Rebecca S Hofford; Qiwen Kang; Richard J Kryscio; Joshua S Beckmann; Michael T Bardo
Journal:  Drug Alcohol Depend       Date:  2019-12-16       Impact factor: 4.492

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.